A Study Of TL-925 For The Treatment of AC

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 70 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.
Epistemonikos ID: 5c9833c8966f1b30dcd6ef5d286e66923472348a
First added on: May 15, 2024